Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Equity Income: 2018-2022

Historic Equity Income for Theravance Biopharma (TBPH) over the last 4 years, with Jun 2022 value amounting to $28.1 million.

  • Theravance Biopharma's Equity Income rose 28.28% to $28.1 million in Q2 2022 from the same period last year, while for Jun 2022 it was $118.8 million, marking a year-over-year increase of 64.90%. This contributed to the annual value of $104.0 million for FY2021, which is 51.94% up from last year.
  • Theravance Biopharma's Equity Income amounted to $28.1 million in Q2 2022, which was up 12.02% from $25.1 million recorded in Q1 2022.
  • Theravance Biopharma's Equity Income's 5-year high stood at $35.3 million during Q4 2021, with a 5-year trough of $686,000 in Q1 2018.
  • Over the past 3 years, Theravance Biopharma's median Equity Income value was $21.7 million (recorded in 2020), while the average stood at $22.6 million.
  • Data for Theravance Biopharma's Equity Income shows a peak YoY surged of 808.02% (in 2019) over the last 5 years.
  • Theravance Biopharma's Equity Income (Quarterly) stood at $5.4 million in 2018, then spiked by 119.47% to $11.9 million in 2019, then skyrocketed by 69.05% to $20.1 million in 2020, then soared by 75.31% to $35.3 million in 2021, then grew by 28.28% to $28.1 million in 2022.
  • Its Equity Income stands at $28.1 million for Q2 2022, versus $25.1 million for Q1 2022 and $35.3 million for Q4 2021.